基本情報
研究分野
1論文
38-
International Journal of Molecular Sciences 25(11) 2024年6月An angiotensin receptor/neprilysin inhibitor (ARNI), a heart failure treatment, is a combination drug made up of sacubitril, a neprilysin inhibitor, and valsartan, a vascular receptor blocker. No human or veterinary studies regarding the effect of ARNI on renal haemodynamics in the absence of cardiac or renal issues exist. Therefore, we investigated the effect of ARNI on renal haemodynamics in five healthy dogs. ARNI was administered to all five dogs at an oral dose of 20 mg/kg twice daily for 4 weeks. Renal haemodynamics were assessed on the day before ARNI administration (BL), on Day 7, and on Day 28. The glomerular filtration rate (GFR) significantly increased on Day 28 compared to BL and Day 7, whereas renal plasma flow increased on Day 7 and Day 28 compared to BL. Systolic blood pressure significantly decreased between BL and Day 28. Plasma atrial natriuretic peptide (ANP) concentrations increased on Day 7 compared to BL. Additionally, ANP concentrations increased on Day 28 in three of the five dogs. Different ANP concentrations were observed in the remaining two dogs. Both urine output volume and heart rate remained relatively stable and did not exhibit significant change. In conclusion, ARNI may enhance renal haemodynamics in healthy dogs. ARNI could be a valuable drug for treating both heart and kidney disease in dogs.
-
Journal of Small Animal Practice 2023年6月22日
-
Open Veterinary Journal 13(5) 604-604 2023年Background: Plasma N-terminal pro-atrial natriuretic peptide (NT-proANP) and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations may be affected by the hydration status.Aim: This study aimed to evaluate the effect of dehydration on plasma NT-proANP and NT-proBNP concentrations in healthy dogs. Methods: This prospective study included five clinically healthy dogs. Furosemide was administered intravenously at 2–4 mg/kg every 1–2 h until completion of the dehydration model. The dehydration model was considered complete when weight loss was ≥5% and findings of dehydration on physical examination were observed. Plasma NT-proANP and NT-proBNP concentrations were compared at three time points: before the dehydration model was created (point 1), at the completion of the dehydration model (point 2), and when dehydration was judged to have improved (point 3). Association between plasma NT-proANP and NT-proBNP concentrations, and each clinical variable (physical examination, blood pressure, blood chemistry, blood gases, and echocardiography) was assessed using linear regression analysis. Results: Plasma NT-proANP concentration decreased significantly from point 2 to point 1 (p < 0.05), whereas plasma NT-proBNP concentration showed a decreasing trend but did not differ significantly between points 1 and 2. Plasma NT-proANP concentration correlated significantly with body weight (R2 = 0.178) and plasma NT-proBNP concentration (R2 = 0.284) (p < 0.05, respectively), and plasma NT-proBNP concentration correlated significantly with electrolytes (sodium, R2 = 0.439; potassium, R2 = 0.444; chloride, R2 = 0.419), and echocardiographic parameters (diastolic left ventricular internal diameter [LVIDd], R2 = 0.519; weight-standardised LVIDd, R2 = 0.535) (p < 0.01, respectively). Conclusion: The plasma NT-proANP concentrations decreased with dehydration. However, the plasma NT-proBNP concentration did not change with mild dehydration and reflected left ventricular morphology.
-
Veterinary record open 9(1) e28 2022年12月BACKGROUND: Ivabradine is used to treat tachycardia; unlike atenolol, it does not affect blood pressure or myocardial contractility. This study compared the impact of ivabradine and atenolol on heart rate (HR) and HR variability (HRV) during a 24 h period, feeding and sleeping times, via a Holter electrocardiogram in healthy cats. We hypothesised that ivabradine and atenolol would lower the HRs equally well, even at times of excitement and rest, such as during feeding and sleep; that ivabradine, unlike atenolol, would have an effect on HRV. METHODS: Five clinically healthy cats were used in the prospective blinded crossover study receiving 3 days of ivabradine (0.30 mg/kg per os twice daily) followed by atenolol (6.25 mg/cat per os twice daily, range 1.3-2.0 mg/kg) or receiving atenolol followed by ivabradine. A placebo period was initiated before the start of the crossover test, data obtained during that period were used as a baseline (BL). Evaluation parameters included HR and HRV, for the whole 24 h period and for feeding and sleeping times, comparing the effect of ivabradine and atenolol with BL. RESULTS: The HR for the whole 24 h, feeding and sleeping times, were significantly lower with ivabradine and atenolol, compared to BL (p < 0.05). The HRV for the whole 24 h and sleeping time were significantly higher after ivabradine compared with BL and after atenolol. CONCLUSIONS: In healthy cats, ivabradine and atenolol significantly reduced the HR regardless of excitement and rest; their effects were comparable. Ivabradine significantly increased HRV in comparison to BL whereas atenolol did not.
-
Veterinary World 15(8) 2072-2083 2022年8月27日Background and Aim: Electrocardiography (ECG) is an adjunct for cardiac enlargement diagnosis. However, its efficacy in assessing left cardiac remodeling (left atrial and left ventricular enlargement) in dogs with myxomatous mitral valve disease (MMVD) remains unclear. This study aimed to evaluate the association between ECG parameters and left cardiac remodeling and to investigate whether the rate of change in ECG waveforms in the same individual reflected left cardiac remodeling in dogs with MMVD.Materials and Methods: This retrospective study included 20 healthy dogs and 140 dogs with MMVD. Data on clinical variables were obtained through physical examination, thoracic radiography, and echocardiography. The ECG parameters were the P-wave duration, PR interval, QRS complex duration, P-wave amplitude, R-wave amplitude, and mean electrical axis. Dogs with examination data that could be obtained multiple times during the study period were classified into the non-progressive and progressive groups.Results: Only the P-wave and QRS complex durations were selected as significant variables associated with imaging test parameters (p < 0.05); they had a relatively higher discriminatory ability for the left cardiac remodeling than other ECG parameters. The rates of change in the PR interval and R-wave amplitude were significantly higher in the progressive group than in the non-progressive group.Conclusion: In dogs with MMVD, the P-wave and QRS complex durations were significantly correlated with the left cardiac remodeling indicators. Furthermore, an increased rate of change in the PR interval and R-wave amplitude in the same individual may indicate left cardiac remodeling.
MISC
274-
Infovets : information for veterinarians = インフォベッツ : よりよい小動物医療環境の創成をめざす臨床情報誌 21(4) 14-21 2018年7月
-
Infovets : information for veterinarians = インフォベッツ : よりよい小動物医療環境の創成をめざす臨床情報誌 21(4) 6-12 2018年7月
-
Journal of Veterinary Pharmacology and Therapeutics 41(3) 457-462 2018年6月1日Basic information related to the pharmacokinetics of sildenafil in dogs is scarce. This study aimed to describe the pharmacokinetic properties of oral sildenafil and determine the effect of feeding and dose proportionality. The effect of feeding on pharmacokinetics of sildenafil (1 mg/kg) was investigated using a crossover study with six dogs. In addition, the dose proportionality of sildenafil ranging 1–4 mg/kg was evaluated using five dogs in the fasted states. The plasma concentrations of sildenafil were determined using high-performance liquid chromatography, and pharmacokinetic parameters were calculated using a noncompartmental analysis. Sildenafil administrations were well tolerated in all studies. Feeding reduced the area under the curve extrapolated to infinity (AUCinf) and the maximum plasma concentration (Cmax) significantly. The elimination half-life (T1/2) did not differ between the fasted and the fed states. For dose proportionality, nonproportional increases in AUCinf and Cmax at 1–4 mg/kg doses were detected by a power model analysis.
-
日本獣医腎泌尿器学会誌 10(1) 23-29 2018年1月30日腎性貧血は、進行した慢性腎臓病(CKD)のイヌおよびネコで一般的に認められる合併症である。腎性貧血は、ネコでは生存期間の短縮と関連しており、重度の貧血はCKD症例のQOLの低下と関連すると思われ、腎性貧血を把握し、改善することは、CKD症例のQOLの改善、そしてCKDの進行抑制、生存期間の延長につながることが期待される。主要な腎性貧血の原因は、腎臓でのEPOの産生が低下することであるが、機能的および絶対的な鉄欠乏も腎性貧血の発生に関与する。そのため、腎性貧血の治療には、EPO製剤に加えて鉄補給も行われる。しかし、獣医療では腎性貧血の鉄欠乏に関する研究、知識が不足し、そしてその治療法は確立されていない。今後、腎性貧血に対する適切な診断法およびその治療法の確立が必要である。(著者抄録)
-
日本獣医腎泌尿器学会誌 10(1) 44-49 2018年1月30日テルミサルタン(TEL)はアンジオテンシンII受容体拮抗薬の1つである。慢性腎臓病のネコではTELの抗蛋白尿効果が報告されているが、イヌでの効果は不明である。今回、我々は、蛋白漏出性腎症(PLN)のイヌに対してTELを投与した場合の抗蛋白尿効果および有害事象を評価した。結果として、イヌでもTELの抗蛋白尿効果が証明され、蛋白尿が寛解(尿蛋白/クレアチニン比<0.5)した症例もいた。有害事象としては高カリウム血症が最も多く認められた。(著者抄録)
-
日本獣医腎泌尿器学会誌 10(1) 44-49 2018年1月テルミサルタン(TEL)はアンジオテンシンII受容体拮抗薬の1つである。慢性腎臓病のネコではTELの抗蛋白尿効果が報告されているが、イヌでの効果は不明である。今回、我々は、蛋白漏出性腎症(PLN)のイヌに対してTELを投与した場合の抗蛋白尿効果および有害事象を評価した。結果として、イヌでもTELの抗蛋白尿効果が証明され、蛋白尿が寛解(尿蛋白/クレアチニン比<0.5)した症例もいた。有害事象としては高カリウム血症が最も多く認められた。(著者抄録)
-
日本獣医腎泌尿器学会誌 10(1) 23-29 2018年1月腎性貧血は、進行した慢性腎臓病(CKD)のイヌおよびネコで一般的に認められる合併症である。腎性貧血は、ネコでは生存期間の短縮と関連しており、重度の貧血はCKD症例のQOLの低下と関連すると思われ、腎性貧血を把握し、改善することは、CKD症例のQOLの改善、そしてCKDの進行抑制、生存期間の延長につながることが期待される。主要な腎性貧血の原因は、腎臓でのEPOの産生が低下することであるが、機能的および絶対的な鉄欠乏も腎性貧血の発生に関与する。そのため、腎性貧血の治療には、EPO製剤に加えて鉄補給も行われる。しかし、獣医療では腎性貧血の鉄欠乏に関する研究、知識が不足し、そしてその治療法は確立されていない。今後、腎性貧血に対する適切な診断法およびその治療法の確立が必要である。(著者抄録)
-
日本獣医麻酔外科学雑誌 48(Supplement 2) 235 2017年11月20日
-
日本獣医麻酔外科学雑誌 48(Suppl.2) 235-235 2017年11月
-
Clinic note : journal of clinical daily treatment for small animals 13(7) 6-23 2017年7月
書籍等出版物
2講演・口頭発表等
25担当経験のある科目(授業)
1-
- 現在獣医泌尿器・生殖器病学 (日本獣医生命科学大学)